AI in Healthcare Statistics (2026)
A hospital says it uses predictive AI. A physician says they use an AI tool only rarely. A regulator authorizes hundreds of devices. Those statements can all be true, but they do not describe the same thing.
Here is the short answer for anyone looking for AI in healthcare statistics: use is growing, but there is no defensible single adoption rate. The most useful 2026 picture separates hospital and firm adoption, clinician and consumer use, regulatory authorization, and evidence of patient outcomes.
AI in healthcare statistics at a glance
71% of U.S. non-federal acute-care hospitals reported using predictive AI integrated into their EHR in 2024, up from 66% in 2023. The underlying survey had informative responses from 2,080 hospitals in 2024 and 2,425 in 2023. This is reported use of predictive AI in EHRs, not all healthcare AI. (ASTP/ONC Data Brief No. 80)
8.3% of U.S. healthcare firms reported current AI use in 2025 in a JAMA Health Forum analysis of 119,300 firm-level responses collected from September 2023 through May 2025. This is a firm-level measure, not a hospital measure. (Open full text in PMC)
258 AI medical devices were authorized by the FDA in 2025, according to Stanford HAI’s 2026 AI Index. This is a one-year authorization flow, not a deployment or patient-benefit measure. (Stanford HAI’s medicine chapter)
A PLOS Digital Health analysis of 1,357 FDA-cleared AI devices through December 5, 2025 linked 34 devices (2.5%) to registered prospective trials, 12 (0.9%) to posted results, 12 (0.9%) to peer-reviewed publications, and 3 (0.2%) to patient-centered outcomes. These are public evidence links, not device failure rates. (PLOS Digital Health)
In a European Commission study surveying 300 healthcare providers, 94% said they were already using AI solutions or planning to adopt them. Because the measure combines use with intention, it is not a current-deployment rate. (European Commission)
In a June 2–14, 2025 survey of 571 UK physicians, 16% reported daily clinical AI use, 15% weekly use, 6% monthly use, 33% rare use, and 30% no use. These are self-reported UK physician responses. (Royal College of Physicians)
32% of U.S. adults in KFF’s February 24–March 2, 2026 poll said they had turned to AI for health information or advice; 29% used it for physical-health information and 16% for mental-health information. This is consumer use, not clinical deployment. (KFF)
34% of 3,488 U.S. adults surveyed by Pew Research Center on June 22–28, 2026 said they had used AI chatbots for at least one of eight health or medical reasons; 25% used them to help identify symptom causes. This is also consumer use, measured with a different question. (Pew Research Center)
The European Commission study projects AI-powered diagnostic-tool adoption in the EU to approach 80% by 2029. It is a forecast, not a current observation.
Get the Mobile Testing Playbook Used by 800+ QA Teams
Discover 50+ battle-tested strategies to catch critical bugs before production and ship 5-star apps faster.
Why healthcare AI adoption statistics differ
The 71% hospital figure and the 8.3% healthcare-firm figure should not be averaged. They use different units of analysis, survey questions, and definitions of AI.
The U.S. hospital measure is specifically about predictive AI integrated into the EHR. In the federal data brief, predictive AI means statistical analysis and machine learning that classifies a patient or produces an individual risk score, such as for readmission risk, early disease detection, appointment no-shows, or treatment recommendations.
The firm figure measures reported current AI use across a healthcare-sector business sample that extends beyond hospitals. It is a valuable business-sector anchor, but it cannot answer how many hospitals use predictive AI.
Physician surveys answer another question: whether clinicians report using an AI tool in their own practice. Consumer polls answer whether people seek health information or advice from AI. Neither is a measure of provider deployment.
Healthcare AI adoption and use by population
U.S. hospitals and healthcare firms
For hospital operations, the 2024 ASTP/ONC result is the clearest U.S. statistic in this set: 71% of surveyed non-federal acute-care hospitals reported EHR-integrated predictive AI use. It signals broad use of this defined category inside surveyed hospitals, not universal use of generative AI or every other AI tool.
For business adoption, the JAMA Health Forum analysis reported 8.3% current AI use among U.S. healthcare firms in 2025. Keeping both measures visible is more useful than forcing them into a single headline rate: one describes hospitals’ EHR-integrated predictive models, while the other describes firms across the sector.
European providers and UK physicians
The Commission’s 94% provider result is best read as an indicator of momentum. It combines organizations already using AI with those planning adoption, so it cannot establish that 94% have deployed an AI tool.
The UK physician data shows a more uneven pattern at the individual-clinician level. Daily use was reported by 16% of respondents, while 30% said they never used AI tools in clinical practice. In the same survey, 70% were very or somewhat supportive of wide NHS implementation. Support, use, and organizational rollout are separate measures.
U.S. consumers
Patients may encounter healthcare AI outside a clinical workflow. KFF’s early-2026 measure concerns people who turned to AI for health information or advice, while Pew’s June 2026 measure asks whether respondents had ever used chatbots for any of eight health or medical reasons.
You should not treat the 32% and 34% results as conflicting rates. Their questions, field dates, and definitions differ. More importantly, neither result establishes that an AI tool was used by a clinician or embedded in a healthcare organization.
AI medical-device authorization and clinical evidence
Authorization is not adoption, and adoption is not patient benefit.
Stanford HAI’s count of 258 FDA-authorized AI medical devices in 2025 describes regulatory activity over one year. It does not reveal routine use, clinical effectiveness, or outcomes across those devices.
The PLOS analysis answers a narrower evidence question. Among its analyzed 1,357-device set, public links to registered prospective trials, posted results, peer-reviewed publications, and patient-centered outcome evaluations were uncommon. That finding does not establish that unlinked devices are ineffective. It establishes that the investigators could link relatively few of the analyzed devices to those forms of public evidence.
The FDA also says that its AI-enabled-device list is intended to identify devices authorized for marketing in the United States and is not a comprehensive resource. A list-derived total is therefore not a complete census of every relevant device. (FDA’s AI-enabled-device list)
The evidence is not exclusively negative. Stanford HAI describes a randomized trial involving 150 diabetes patients in which 71% achieved healthy blood sugar levels over one year while safely reducing medication. That is a result for a particular intervention and study population, not an effectiveness rate for healthcare AI as a category.
What physicians report about implementation barriers
The Royal College of Physicians survey separates enthusiasm from implementation conditions. Among 551 UK physician respondents asked about training, 79% said they needed training in clinical AI tools.
Among 548 respondents asked about access, 66% said they did not have access to clinical AI tools and 6% said they did. Among 541 respondents asked about barriers to deployment, 74% cited lack of clinical AI expertise, 70% cited inability to integrate tools with systems such as electronic patient records, and 65% cited poor interoperability. These are reported implementation barriers, not independently measured infrastructure-failure rates.
For your planning, that distinction matters. A favorable attitude toward AI does not supply training, access, integration, governance, or evidence that a specific workflow improves patient care.
AI in healthcare forecasts
Forecasts belong in a different category from observed use.
The European Commission study projects AI-powered diagnostic-tool adoption in the EU to approach 80% by 2029. It also projects the EU digital-health market to grow from EUR 11 billion in 2023 to EUR 61.2 billion by 2035. The latter is a forecast for the EU digital-health market, not a reported global AI-in-healthcare revenue figure.
Use these projections for scenario planning, not to describe present adoption. A forecast depends on a model and assumptions; a survey observation describes what its defined respondents reported at a particular time.
How to interpret AI in healthcare statistics
Term | What it measures here | What it does not prove |
Adoption or use | A hospital, firm, physician, provider, or consumer reports using an AI tool or model | That the tool improves outcomes or is used by every organization in the category |
Planned adoption | A respondent says adoption is intended | Current deployment |
Authorization or clearance | A regulator permits a device to be marketed under a specified pathway | Hospital deployment, clinical utility, or patient benefit |
Validation | A trial, result, publication, or other evidence link exists | That every deployment works in every population |
Patient-centered outcome | An evaluation measures mortality, morbidity, readmission, or another patient endpoint | A universal outcome rate for healthcare AI |
Attitude or readiness | Support, training need, access, or a perceived barrier | Actual use or measured system performance |
Forecast | A study projects a future value | A current observation |
This taxonomy is a practical guardrail for a deck, budget request, or product decision. Label the number by what it measures before comparing it with another number.
What the evidence still does not show
No public source in this set supports a single global adoption rate for AI in healthcare. The underlying populations are hospitals, firms, clinicians, providers, and consumers; the geographies, time windows, and definitions also differ.
The public record also lacks a complete, consistently dated mapping from every authorized AI medical device to registered prospective trials, posted results, peer-reviewed publications, and patient-centered outcomes. A dataset with those links, a stated denominator, and published inclusion rules would make cross-device evidence far easier to assess.
Quash has no first-party dataset on healthcare AI adoption, clinical outcomes, healthcare QA defects, or customer results that applies to this question. Rather than infer a number, this report relies on the public sources above and leaves that first-party evidence gap explicit.
Methodology and source notes
This report uses an official U.S. government data brief, an open-access peer-reviewed study, a university AI index, a peer-reviewed evidence-linkage analysis, an EU Commission study, a professional-college survey, public-opinion polling, and FDA guidance.
The numbers remain in their original lanes. Hospital use is reported for 2024; firm use for 2025; UK physician fieldwork ran June 2–14, 2025; KFF fieldwork ran February 24–March 2, 2026; and Pew fieldwork ran June 22–28, 2026. The PLOS device analysis covered clearances through December 5, 2025.
Conclusion
The useful conclusion is not that one adoption percentage “wins.” Healthcare AI is expanding across hospitals, firms, clinicians, consumers, and regulated devices, but each statistic answers a different question. When you need a figure, choose the population and evidence type that match your decision—then keep authorization, reported use, and patient outcomes separate.
Continue reading
More articles from the Quash editorial desk.
